Why West Pharmaceutical Services Stock Was Blasting Higher on Thursday

Core Viewpoint - West Pharmaceutical Services reported better-than-expected quarterly results, leading to a significant increase in share price by nearly 11% [1] Financial Performance - The company achieved net sales of just under $805 million in Q3, an increase of nearly 8% year over year [2] - Net income rose by 3% to $140 million, with adjusted earnings per share increasing from $1.85 to $1.96 [2][3] Analyst Expectations - The reported figures surpassed both the company's own expectations and those of analysts, who had anticipated net sales of slightly over $786 million and adjusted earnings of $1.69 per share [3] Future Guidance - West Pharmaceutical raised its revenue guidance for 2025 to a range of $3.06 billion to $3.07 billion, up from the previous estimate of $3.04 billion to $3.06 billion [4] - The adjusted net income forecast was also increased to a range of $7.06 to $7.11 per share, significantly above the prior estimate of $6.65 to $6.85 [4] Analyst Consensus - The low end of the new revenue and profitability ranges exceeds the average analyst estimates, which are just under $3.05 billion for revenue and $6.78 per share for adjusted profitability [5]